Yanagisawa Chie, Hanaki Hideaki, Natae Taiji, Sunakawa Keisuke
Kitasato Research Center for Anti-infection Drugs, 5-9-1 Shirokane, Minato-Ku, Tokyo 108-0072, Japan.
J Infect Chemother. 2007 Dec;13(6):368-72. doi: 10.1007/s10156-007-0551-6. Epub 2007 Dec 25.
Human-origin intravenous immunoglobulin (IVIG) collected from healthy individuals was tested for its neutralizing activity against the hemolysin, toxic shock syndrome toxin-1 (TSST-1), and enterotoxins, produced by laboratory strains of methicillin-resistant Staphylococcus aureus (MRSA). The hemolytic activity of the culture supernatant against sheep red blood cells was reduced from 100% to 5.5% relative hemolysis in the presence of 0.156 mg protein/ml of IVIG. The maximum dilution endpoint of the culture supernatant for TSST-1-mediated latex aggregation was 32-fold. This level of TSST-1 activity was reduced to eightfold dilution by 0.78 mg protein/ml of IVIG, and the latex aggregation activity of undiluted TSST-1 in the culture supernatant was inhibited by 1.56 mg protein/ml of IVIG. Similarly, the enterotoxin A-mediated latex aggregation titer appeared to be a 320-fold dilution. This toxin activity was reduced to an 80-fold dilution and below a tenfold dilution by 0.049 through 0.78 and 1.56 mg protein/ml, respectively, of IVIG. These results show that IVIG has powerful neutralizing activity against hemolysin, TSST-1, and enterotoxin A. Therefore, IVIG may be useful for passive immunization therapy in patients suffering from diseases caused by MRSA exotoxins.
对从健康个体收集的人源静脉注射免疫球蛋白（IVIG）进行了测试，以检测其对耐甲氧西林金黄色葡萄球菌（MRSA）实验室菌株产生的溶血素、毒性休克综合征毒素-1（TSST-1）和肠毒素的中和活性。在存在0.156mg蛋白质/ml的IVIG时，培养上清液对绵羊红细胞的溶血活性从100%相对溶血降低至5.5%。TSST-1介导的乳胶凝集培养上清液的最大稀释终点为32倍。这种水平的TSST-1活性在0.78mg蛋白质/ml的IVIG作用下降低至8倍稀释，培养上清液中未稀释的TSST-1的乳胶凝集活性在1.56mg蛋白质/ml的IVIG作用下受到抑制。同样，肠毒素A介导的乳胶凝集效价似乎为320倍稀释。分别在0.049、0.78和1.56mg蛋白质/ml的IVIG作用下，这种毒素活性降低至80倍稀释和低于10倍稀释。这些结果表明，IVIG对溶血素、TSST-1和肠毒素A具有强大的中和活性。因此，IVIG可能对患有由MRSA外毒素引起疾病的患者的被动免疫治疗有用。
